Rein Therapeutics (ALRN), formerly Aileron Therapeutics, said Friday that it changed names to reflect its focus on developing first-in-class treatments for rare pulmonary and fibrosis diseases.
The company's stock will begin trading under the new Nasdaq ticker "RNTX" on Monday, it added.
The company also said its key goals for 2025 include initiating a phase 2 trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis in H1.
Shares of the company rose 4.7% in recent trading activity.
Price: 2.02, Change: +0.09, Percent Change: +4.66
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.